Tag: 200-300

On October 30, 2020, Yang, Chuluo; Ni, Fan published a patent.Electric Literature of 160377-42-4 The title of the patent was Chiral organic luminescent material and application thereof in electronic device. And the patent contained the following:

The title chiral organic luminescent material has a structural formula I as shown in claim 1, wherein A1 is alkenyl alkynyl, amino, etc.; A2 is alkenyl alkynyl, amino, etc.; R1-R3 are independently selected from hydrogen, deuterium, etc.; and A1, A2, R1, R2 and R3 are not connected or bonded via covalent bonds. The charge transfer-state chiral organic luminescent material with a D-A structure is formed by introducing a suitable electron acceptor (A) into chiral dihydroindenoacridine as an electron donor (D). The chiral dihydroindenoacridine as the D has large steric hindrance, is favorable for forming large torsion between D and A so as to reduce overlap of frontier mol. orbits, to further reduce the singlet-triplet energy level difference (ΔEST), activate the reverse intersystem crossing process so as to realize delayed fluorescence emission, and improve the exciton utilization rate of the device. The rigid chiral quaternary carbon in the chiral dihydroindenoacridine can enable the chiral organic light-emitting material to have circularly polarized luminescent properties, so that an organic electroluminescent device based on the chiral dihydroindenoacridine has circularly polarized luminescent properties, and effective guarantee is provided for electroluminescence to pass through a quarter-wave plate and a polarizing plate. The chiral organic luminescent material can be applied to electronic devices such as the organic light-emitting device, organic solar cell, organic field effect transistor, organic light emitting field-effect transistor, organic laser, organic sensor or organic spin electronic device. The experimental process involved the reaction of 5-(4-Bromophenyl)pyrimidine(cas: 160377-42-4).Electric Literature of 160377-42-4

The Article related to chiral organic luminescent material preparation oled, Heterocyclic Compounds (More Than One Hetero Atom): Triazines and other aspects.Electric Literature of 160377-42-4

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

On September 25, 2014, Chan, Bryan; Estrada, Anthony; Shore, Daniel; Sweeney, Zachary published a patent.Formula: C8H10BrN3O The title of the patent was Preparation of pyrazolopyridine compounds as LRRK2 inhibitors. And the patent contained the following:

The invention relates to pyrazolopyridine compounds of formula I and II, or pharmaceutically acceptable salts thereof that are useful for the treatment of the diseases associated with LRRK2. Compounds of formula I and II wherein R1 is (un)substituted alkyl, heterocycloalkyl, cycloalkyl, etc.; for formula I, one, two, or three of X1-X4 are N and the remainder are each independently CR2; or X1-X4 are independently CR2; for formula II, X4 is C or N; and one or two of X1-X3 are independently N or NR8, and the remainder are each independently CR2; each R2 is independently H, alkyl, cyano, halo, heteroaryl, OR4, CONR5R6, SO2R7, etc.; each R8 is independently H or (un)substituted alkyl; R4-R7 are independently H or alkyl; R5 and R6 together with nitrogen to which they are attached are linked to form a ring; are claimed. Example compound III was prepared by cyclocondensation of compound IV with hydrazine hydrate, followed by deprotection in 25% yield over two steps. The invention compounds were evaluated for the LRRK2 inhibitory activity and compound III shows 0.0005 μM of Ki. The experimental process involved the reaction of 4-(2-Bromopyrimidin-4-yl)morpholine(cas: 1209459-32-4).Formula: C8H10BrN3O

The Article related to pyrazolopyridine preparation lrrk2 inhibitor, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazoles and other aspects.Formula: C8H10BrN3O

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

On January 22, 2019, Xing, Qifeng; Li, Zhiyang; Liu, Shuyao; Ren, Xueyan published a patent.HPLC of Formula: 160377-42-4 The title of the patent was Preparation of pyrazoloindazole derivatives and their application in OLED. And the patent contained the following:

The invention relates to pyrazoloindazole derivative of formula I [wherein Ar1 = H, (un)substituted C6-30 aryl or fused aryl, and (un)substituted C3-30 heteroaryl or fused heteroaryl; Ar2 = (un)substituted C6-30 aryl or fused aryl, and (un)substituted C3-30 heteroaryl or fused heteroaryl], method for their preparation and their application in OLED. The inventive compound can be applied in OLED to effectively reduce the work voltage and improve the light-emitting efficiency of the OLED. The experimental process involved the reaction of 5-(4-Bromophenyl)pyrimidine(cas: 160377-42-4).HPLC of Formula: 160377-42-4

The Article related to pyrazoloindazole derivative preparation oled, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazoles and other aspects.HPLC of Formula: 160377-42-4

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

On January 12, 2018, Wang, Fang; Li, Chong; Zhang, Zhaochao; Zhang, Xiaoqing published a patent.Computed Properties of 160377-42-4 The title of the patent was Organic compound based on triazine and quinoxaline and its application in organic light-emitting device. And the patent contained the following:

The invention relates to organic compound based on triazine and quinoxaline and its application in organic light-emitting device. The inventive organic compound has high glass transition temperature and mol. thermal stability, has low light absorption and high refractive index in visible light field, and can effectively improve light extraction efficiency of OLED device when applied in CPL layer of OLED device. The inventive compound has deep HOMO level and a high electron mobility, can be applied as hole blocking/electron transporting layer material of OLED device, and can effectively block transportation of hole or energy from light-emitting layer to the side of electron layer, thereby improving recombination efficiency of holes and electrons in light-emitting layer and improving light-emitting efficiency and service life of OLED device. The experimental process involved the reaction of 5-(4-Bromophenyl)pyrimidine(cas: 160377-42-4).Computed Properties of 160377-42-4

The Article related to triazine quinoxaline preparation oled, Heterocyclic Compounds (More Than One Hetero Atom): Triazines and other aspects.Computed Properties of 160377-42-4

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

On December 23, 2021, Arasappan, Ashok; Bell, Ian M.; Bungard, Christopher James; Burgey, Christopher S.; Cox, Jason M.; Kelly, Michael J., III; Layton, Mark E.; Liu, Hong; Liu, Jian; Perkins, James J.; Shah, Akshay A.; Vanheyst, Michael David; Wu, Zhe published a patent.Safety of 2,5-Dichloro-4-(trifluoromethyl)pyrimidine The title of the patent was 2-Oxoimidazolidine-4-carboxamides as NaV1.8 inhibitors and their preparation. And the patent contained the following:

Compounds of formula I, and the pharmaceutically acceptable salts thereof, are inhibitors of Nav1.8 channel activity and may be useful in the treatment, prevention, management, amelioration, control and suppression of diseases mediated by Nav1.8 channel activity. The compounds of the invention may be useful in the treatment, prevention or management of pain disorders, cough disorders, acute itch disorders, and chronic itch disorders. Compounds of formula I wherein one of A and B is (un)substituted aryl and (un)substituted heteroaryl, and the other one of A and B is (un)substituted aryl, (un)substituted heteroaryl, (un)substituted C1-6 alkyl-aryl, (un)substituted C3-8 cycloalkyl-aryl, etc.; R1, R2, R3 and R4 are independently H, (un)substituted C1-6 alkyl, (un)substituted C3-6 alkenyl, (un)substituted C3-6 alkynyl, (un)substituted C3-10 cycloalkyl, etc.; R5 is H and (un)substituted C1-6 alkyl; R6 is H, (un)substituted C1-6 alkyl, (un)substituted C3-6 cycloalkyl and (un)substituted C2-6 cycloheteroalkyl; R7 is H, (un)substituted C1-6 alkyl, (un)substituted C2-6 alkenyl and (un)substituted C2-6 alkynyl; and pharmaceutically acceptable salts thereof, are claimed. Example compound II was prepared by a multistep procedure (procedure given). The invention compounds were evaluated for their NaV1.8 inhibitory activity (data given). The experimental process involved the reaction of 2,5-Dichloro-4-(trifluoromethyl)pyrimidine(cas: 785777-98-2).Safety of 2,5-Dichloro-4-(trifluoromethyl)pyrimidine

The Article related to oxoimidazolidinecarboxamide preparation sodium channel inhibitor, Heterocyclic Compounds (More Than One Hetero Atom): Imidazoles and other aspects.Safety of 2,5-Dichloro-4-(trifluoromethyl)pyrimidine

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

On September 26, 2013, Chan, Bryan; Estrada, Anthony; Shore, Daniel; Sweeney, Zachary published a patent.Recommanded Product: 4-(2-Bromopyrimidin-4-yl)morpholine The title of the patent was Preparation of pyrazolopyridines for treatment of Parkinsons disease. And the patent contained the following:

The title compounds I or II [R1 = (un)substituted alkyl, monocyclic heterocycloalkyl, bicyclic heterocycloalkyl, cycloalkyl; for I: 1-3 of X1-X4 = N, and the remainder are each CR2; for II: X4 = C or N, and 1-2 of X1-X3 = N and NR8, and the remainder = CR2, such that X1-X4 and N form a heteroaryl; R2 = H, alkyl, CN, halo, etc.; R8 = H, (un)substituted alkyl; with the proviso], useful for the prevention or treatment of a disorder caused by, associated with or accompanied by abnormal kinase activity, preferably abnormal LRRK2 activity, were prepared E.g., a multi-step synthesis of III, starting from 4-chloro-3-iodo-1H-pyrazolo[4,3-c]pyridine, was described. Exemplified compounds I and II were tested for their LRRK2 activity (data given). Pharmaceutical compositions comprising compound I or II, alone or in combination with other therapeutic agent, were disclosed. The experimental process involved the reaction of 4-(2-Bromopyrimidin-4-yl)morpholine(cas: 1209459-32-4).Recommanded Product: 4-(2-Bromopyrimidin-4-yl)morpholine

The Article related to pyrazolopyridine preparation lrrk2 inhibitor antiparkinsonian combination chemotherapy, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazoles and other aspects.Recommanded Product: 4-(2-Bromopyrimidin-4-yl)morpholine

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

On October 6, 2016, Jones, Alison; Kemp, Mark; Stockley, Martin; Gibson, Karl; Whitlock, Gavin published a patent.Category: pyrimidines The title of the patent was 1-Cyanopyrrolidine compounds as USP30 inhibitors and their preparation. And the patent contained the following:

The invention relates to compounds of formula I and method for the manufacture of inhibitors of deubiquitylating enzymes. In particular, the invention relates to the inhibition of ubiquitin C-terminal hydrolase 30 (USP30). The invention further relates to the use of DUB inhibitors in the treatment of conditions involving mitochondrial dysfunction and cancer. Compounds of formula I wherein Z is absent and CR6R7; Y is a bond, C0-3 alkylene-NR11-C0-3 alkylene and (un)substituted C1-3 alkylene; R1, R6, R7 and R8 are independently H, F, CN, OH, (un)substituted C1-3 alkyl and (un)substituted C1-3 alkoxy; R2 is H, (un)substituted C1-6 alkyl, (un)substituted C1-6 alkoxy, (un)substituted 4- to 10-membered heteroaryl, etc.; R3, R4 and R5 are independently (un)substituted alkyl and (un)substituted C1-3 alkoxy; R9 is H, CN, OH, (un)substituted C1-6 alkyl, etc.; R10 is H, (un)substituted C1-6 alkyl; R11 is H, (un)substituted C1-6 alkyl, 4- to 10-membered heteroaryl, heterocyclyl, aryl, etc.; R9R10 can be taken together to form (un)substituted heterocyclic ring; R10R11 can be taken together to form (un)substituted (mono/bi)cyclic ring; R12 is (un)substituted (mono/bi/tri)cyclic 3- to 14-membered heteroaryl, heterocyclyl, cycloalkyl and aryl; and pharmaceutically acceptable salts thereof, are claimed. Example compound II was prepared by amidation of 5-phenylpyridine-2-carboxylic acid with (R)-3-amino-1-(tert-butoxycarbonyl)pyrrolidine; the resulting tert-Bu (R)-3-(5-phenylpicolinamido)pyrrolidine-1-carboxylate underwent hydrolysis to give (R)-5-phenyl-N-(pyrrolidin-3-yl)picolinamide TFA, which underwent cyanation to give compound II. The invention compounds were evaluated for their USP30 inhibitory activity (data given). The experimental process involved the reaction of 5-Phenylpyrimidine-2-carboxylic acid(cas: 85386-20-5).Category: pyrimidines

The Article related to cyanopyrrolidine preparation usp30 inhibitor, Heterocyclic Compounds (One Hetero Atom): Pyrroles and Pyrrolizines and other aspects.Category: pyrimidines

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

On August 5, 2021, Saulnier, Mark George; Chen, Jesse Jingyang; Karra, Srinivasa; Sprott, Kevin Tyler; Wiles, Jason Allan; Ray, Soumya published a patent.SDS of cas: 785777-98-2 The title of the patent was ASGPR-binding compounds for the degradation of extracellular proteins. And the patent contained the following:

Compounds and compositions that have an asialoglycoprotein receptor (ASGPR) binding ligand bound to an extracellular protein binding ligand for the selective degradation of the target extracellular protein in vivo to treat disorders mediated by the extracellular protein are described. The experimental process involved the reaction of 2,5-Dichloro-4-(trifluoromethyl)pyrimidine(cas: 785777-98-2).SDS of cas: 785777-98-2

The Article related to asgpr ligand preparation extracellular protein degradation disease therapy, Pharmacology: Effects Of Inflammation Inhibitors and Immune Agents and other aspects.SDS of cas: 785777-98-2

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

On December 3, 2021, Guo, Jianhua; Li, Mengru; Lu, Ying; Sun, Yue published a patent.Recommanded Product: 160377-42-4 The title of the patent was Preparation of compounds containing benzo five membered heterocycles and organic electroluminescent devices. And the patent contained the following:

The invention discloses a preparation of compounds containing benzo five membered heterocycles and organic electronic devices, which improves the luminous efficiency of the device and prolongs the service life of the device. The compounds containing benzo five membered heterocycles were shown in formula I, Y is selected from any one of O atom, S atom, C (Rx) 2 and N(Ry); the Rx and Ry are the same or different from each other, and are independently selected from hydrogen, deuterium, cyano, nitro, substituted or unsubstituted C1-C12 alkyl, substituted or unsubstituted C3-C12 cycloalkyl, substituted or unsubstituted C6-C30 aryl, substituted or unsubstituted C3-C30 heteroaryl any one of the rings formed by the condensation of the substituted or unsubstituted aliphatic ring of C3- C30 and the aromatic ring of C6- C30; the two adjacent Rx can be connected to form a substituted or unsubstituted ring, or any of Rx and Ry can be directly bonded with L0; when the Rx and Ry are directly bonded with L0, the Rx and Ry are independently selected from any one of single bond, substituted or unsubstituted C6-C30 arylene, substituted or unsubstituted heteroarylene; the Z is selected from any one of O atom and S atom; the Ar1 is selected from substituted or unsubstituted C3-C12 cycloalkyl, substituted or unsubstituted C3-C12 heterocycloalkyl, etc. The title compound was prepared by a multi-step reaction. The invention discloses an organic electroluminescent device, which comprises the components containing benzo five member heterocycles. The experimental process involved the reaction of 5-(4-Bromophenyl)pyrimidine(cas: 160377-42-4).Recommanded Product: 160377-42-4

The Article related to benzo five membered heterocycle organic electroluminescent device suzuki coupling, Heterocyclic Compounds (More Than One Hetero Atom): Oxazoles, Isoxazoles and other aspects.Recommanded Product: 160377-42-4

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

On July 28, 2011, Eidam, Hilary Schneck; Fox, Ryan Michael published a patent.Safety of 5-Phenylpyrimidine-2-carboxylic acid The title of the patent was TRPV4 antagonists as pharmaceutical agents. And the patent contained the following:

The invention discloses indole or benzothiophene analogs I [R1= C1-3 alkyl, C1-3 alkoxy, CF3, halo, etc.; R2= C1-4 alkyl, CH2C3-6 cycloalkyl, CH2Ph; R3= (un)substituted pyrrole, (un)substituted pyridazine, (un)substituted imidazole, (un)substituted indole, etc.; X= bond, CH2; Y= NR4, S; R4= H, C1-3 alkyl; R5= H, C1-5 alkyl; G= (un)substituted heterocycle, (un)substituted cyclopentyl, (un)substituted cyclohexyl, etc.; i= 0,1,2,3], pharmaceutical compositions containing them and their use as TRPV4 antagonists. The experimental process involved the reaction of 5-Phenylpyrimidine-2-carboxylic acid(cas: 85386-20-5).Safety of 5-Phenylpyrimidine-2-carboxylic acid

The Article related to trpv4 antagonist indole benzothiophene derivative pharmaceutical agent, Pharmacology: Other (All Agents and Effects Not Otherwise Assignable) and other aspects.Safety of 5-Phenylpyrimidine-2-carboxylic acid

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia